Travere Therapeutics
TVTX
119 hedge funds and large institutions have $505M invested in Travere Therapeutics in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 15 closing their positions.
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
3% more funds holding
Funds holding: 116 → 119 (+3)
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
27% less capital invested
Capital invested by funds: $691M → $505M (-$186M)
58% less call options, than puts
Call options by funds: $15.1M | Put options by funds: $35.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$49M |
| 2 |
PA
Perceptive Advisors
New York
|
+$6.37M |
| 3 |
Goldman Sachs
New York
|
+$4.59M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.38M |
| 5 |
SIM
Spark Investment Management
New York
|
+$2.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$11.1M |
| 2 |
BNP Paribas Asset Management
Paris,
France
|
-$6.33M |
| 3 |
Barclays
London,
United Kingdom
|
-$5.91M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.86M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.74M |
TVTX Hedge Fund Activity: Q1 2016 in Review
119 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2016, worth a combined $505M — down 27% from $691M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TVTX positions and 15 closed out — a net gain of 5 holders — while 42 added to existing stakes and 43 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $49M. The largest seller was Consonance Capital Management, cutting an estimated $11.1M.
- 119 institutional investors held Travere Therapeutics (TVTX) as of Q1 2016, up from 116 in Q4 2015.
- Funds reported $505M of Travere Therapeutics stock for Q1 2016, down 27% quarter-over-quarter.
- 20 funds opened new Travere Therapeutics positions in Q1 2016 and 15 closed out, a net change of +5 holders.
- The largest Travere Therapeutics buyer in Q1 2016 was Scopia Capital Management, an estimated $49M added.
- The largest Travere Therapeutics seller in Q1 2016 was Consonance Capital Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2016.